Annual Report 2025

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2025 148 The United Laboratories International Holdings Limited Annual Report 2025 39. MAJOR NON-CASH TRANSACTIONS During the current year, short term borrowings drawn on discounted bills with recourse and bills receivables endorsed to suppliers with full recourse of RMB16,884,000 (2024: RMB23,853,000) and RMB1,111,399,000 (2024: RMB661,921,000), respectively, have been derecognised when the related receivables were matured. Discounted bills with recourse amount of RMB25,532,000 (2024: RMB16,884,000) and bills receivables endorsed to suppliers with full recourse amount of RMB636,987,000 (2024: RMB1,111,399,000) have been recognised for which the maturity dates of the related receivables have not yet fallen due at the end of the reporting period. During the current year, the Group has non-cash additions to right-of-use assets by entering into new lease agreements for the use of leased office and staff quarters ranged from two years to three years (2024: two years to three years). On the lease commencement, the Group recognised RMB1,719,000 (2024: RMB16,294,000) right-of-use assets and RMB1,719,000 (2024: RMB16,294,000) lease liabilities. 40. RELATED PARTY TRANSACTIONS Compensation to key management personnel representing directors’ remuneration has been disclosed in Note 13. During the year, the Group entered into the following transaction with a related party: Name of related party Nature of transaction /balance Relationship 2025 2024 RMB’000 RMB’000 寧波普邦生物科技有限公司 Sales of goods Associate 46,530 4,621 Trade advance Associate – 7,500 Trade and bills receivables Associate 47,308 –